Insider Selling: Cerus Co. (NASDAQ:CERS) CEO Sells 71,086 Shares of Stock

Cerus Co. (NASDAQ:CERS) CEO William Mariner Greenman sold 71,086 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $1.45, for a total value of $103,074.70. Following the completion of the transaction, the chief executive officer now directly owns 4,238,672 shares in the company, valued at $6,146,074.40. The trade was a 1.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

William Mariner Greenman also recently made the following trade(s):

• On Friday, March 7th, William Mariner Greenman sold 60,984 shares of Cerus stock. The stock was sold at an average price of $1.50, for a total value of $91,476.00.
• On Tuesday, March 4th, William Mariner Greenman sold 23,023 shares of Cerus stock. The stock was sold at an average price of $1.55, for a total value of $35,685.65.

Cerus Price Performance

NASDAQ:CERS opened at $1.45 on Tuesday. The stock’s fifty day moving average price is $1.72 and its two-hundred day moving average price is $1.75. Cerus Co. has a 52-week low of $1.38 and a 52-week high of $2.54. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.59. The company has a market cap of $269.40 million, a price-to-earnings ratio of -13.18 and a beta of 1.56.

Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. The firm had revenue of $50.81 million for the quarter, compared to the consensus estimate of $50.81 million. On average, analysts anticipate that Cerus Co. will post -0.08 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Rockport Wealth LLC bought a new stake in shares of Cerus in the 4th quarter valued at $25,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Cerus in the 4th quarter valued at $25,000. Cibc World Markets Corp bought a new stake in shares of Cerus in the 4th quarter valued at $26,000. R Squared Ltd bought a new stake in shares of Cerus in the 4th quarter valued at $29,000. Finally, Virtu Financial LLC bought a new stake in shares of Cerus in the 4th quarter valued at $33,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $4.00 price objective on shares of Cerus in a report on Friday, February 21st.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.